Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 21878429)

1.

Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.

Thiery-Vuillemin A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, Bouchet S, Bazan F, Curtit E, Pivot X.

Ann Oncol. 2011 Sep;22(9):2152-4. doi: 10.1093/annonc/mdr343. No abstract available.

2.

Pharmacokinetics of sunitinib in hemodialysis.

Izzedine H, Etienne-Grimaldi MC, Renée N, Vignot S, Milano G.

Ann Oncol. 2009 Jan;20(1):190-2. doi: 10.1093/annonc/mdn626. Epub 2008 Sep 18. No abstract available.

3.

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.

Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K.

Ann Oncol. 2010 Jun;21(6):1382-3. doi: 10.1093/annonc/mdq150. Epub 2010 Mar 26. No abstract available.

4.

A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.

Richards TM, Plowman PN, Reznek R, Ball SA.

Clin Oncol (R Coll Radiol). 2009 Oct;21(8):633-4. doi: 10.1016/j.clon.2009.03.001. Epub 2009 Apr 19. No abstract available.

PMID:
19380217
5.

Sunitinib rechallenge in metastatic renal cell carcinoma patients.

Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI.

Cancer. 2010 Dec 1;116(23):5400-6. doi: 10.1002/cncr.25583. Epub 2010 Nov 2.

6.

Sunitinib prior to planned cytoreductive nephrectomy: is this the new litmus test for metastatic renal cell carcinoma?

Kim SP, Thompson RH.

Eur Urol. 2011 Sep;60(3):455-6; discussion 456-7. doi: 10.1016/j.eururo.2011.05.056. Epub 2011 Jun 12. No abstract available.

PMID:
21680083
7.

Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice.

Ravaud A, Bello CL.

Anticancer Drugs. 2011 Jun;22(5):377-83. doi: 10.1097/CAD.0b013e3283442039. Review.

PMID:
21394020
8.

Advances in pancreatic neuroendocrine tumor treatment.

Mir O, Coriat R, Goldwasser F.

N Engl J Med. 2011 May 12;364(19):1871; author reply 1873-4. doi: 10.1056/NEJMc1102746#SA1. No abstract available.

PMID:
21561358
9.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.

J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3.

10.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

PMID:
21612860
11.

Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.

Park CY.

Anticancer Drugs. 2009 Oct;20(9):848-9. doi: 10.1097/CAD.0b013e32832fffc7.

PMID:
19644356
12.

[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].

Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.

Aktuelle Urol. 2007 Jul;38(4):328-30. German.

PMID:
17647172
13.

Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.

Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E.

Oncol Rep. 2010 Aug;24(2):507-10.

PMID:
20596640
14.

Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.

Medioni J, Choueiri TK, Zinzindohoué F, Cho D, Fournier L, Oudard S.

J Urol. 2009 Jun;181(6):2470-5; discussion 2475. doi: 10.1016/j.juro.2009.02.020. Epub 2009 Apr 16.

PMID:
19371877
15.

Improvement of actinic keratosis associated with sunitinib therapy for metastatic renal cell carcinoma.

Mir-Bonafé JM, Cañueto J, Bravo J, de Unamuno P.

Int J Dermatol. 2013 Nov;52(11):1445-7. doi: 10.1111/j.1365-4632.2011.05265.x. Epub 2013 Feb 22. No abstract available.

PMID:
23432117
16.

Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.

Kahl C, Hilgendorf I, Freund M, Casper J.

Onkologie. 2008 Sep;31(8-9):485. doi: 10.1159/000142359. Epub 2008 Jul 31. No abstract available.

PMID:
18787358
17.

[A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].

Komeya M, Matsumoto T, Fujinami K, Senga Y, Asakura T, Goto A.

Hinyokika Kiyo. 2010 Sep;56(9):499-503. Review. Japanese.

18.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH.

J Anal Toxicol. 2011 Oct;35(8):558-65.

19.

Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.

Zastrow S, Froehner M, Platzek I, Novotny V, Wirth MP.

Urology. 2009 Apr;73(4):868-70. doi: 10.1016/j.urology.2008.10.028. Epub 2009 Jan 23.

PMID:
19167044
20.

Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.

Hird AE, Chow E, Ehrlich L, Probyn L, Sinclair E, Yip D, Ko YJ.

J Palliat Med. 2008 Oct;11(8):1156-61. doi: 10.1089/jpm.2008.9846.

PMID:
18980461
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk